WO2018210302A1 - 一种苯并呋喃类衍生物游离碱的晶型及制备方法 - Google Patents
一种苯并呋喃类衍生物游离碱的晶型及制备方法 Download PDFInfo
- Publication number
- WO2018210302A1 WO2018210302A1 PCT/CN2018/087272 CN2018087272W WO2018210302A1 WO 2018210302 A1 WO2018210302 A1 WO 2018210302A1 CN 2018087272 W CN2018087272 W CN 2018087272W WO 2018210302 A1 WO2018210302 A1 WO 2018210302A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- group
- crystallization
- crystal
- cancer
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- Lymphoma is a malignant tumor originating from the lymphoid hematopoietic system. It is classified into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) according to the tumor cells.
- NHL non-Hodgkin's lymphoma
- HL Hodgkin's lymphoma
- NHL mainly pathologically. It is a lymphocyte, tissue cell or reticular cell with different degrees of differentiation.
- lymphocyte origins it can be divided into three different clinical types. It is a B cell, T cell and natural killer (NK) cell lymphoma, in which the main function of B cell is to secrete various antibodies to help the body resist various external invasions.
- NK natural killer
- the diffraction angle 2 ⁇ angles are 6.31, 7.24, 8.92, 10.38, 10.99, 12.07, 14.56, 15.10, 16.36, 17.29, 17.94, 19.13, 19.71, 21.12, 21.48, 22.59, 24.15, 25.45, 26.28, 26.52, 27.10, 28.83, 30.07, 31.37, 32.56, 33.65, 34.64, 36.09, 37.13 and 40.04 have characteristic peaks, wherein the error range of each characteristic peak 2 ⁇ is ⁇ 0.2.
- the invention also provides a method for preparing a B crystal form, characterized in that the method is selected from the group consisting of:
- the compound represented by the formula (I) is dissolved in a solvent, crystallized, filtered, and dried to obtain a target B crystal form; the solvent is selected from ethanol; and the crystallization method is selected from room temperature crystallization and cooling. Crystallization, crystallization of volatile solvent or addition of seed crystals induces crystallization.
- the compound represented by the formula (I) is dissolved in a good solvent, an anti-solvent is added, crystallized, filtered, and dried to obtain a target B crystal form;
- the good solvent is selected from ethanol, and the anti-solvent is selected from water.
- the method of crystallization is selected from the group consisting of room temperature crystallization, cooling crystallization, crystallization of a volatile solvent or addition of seed crystals to induce crystallization.
- the present invention further provides a crystal form C of the compound of the formula (I), characterized in that an X-ray powder diffraction pattern represented by a diffraction angle 2 ⁇ angle is obtained using Cu-K ⁇ radiation, and the diffraction angle 2 ⁇ angle is 7.40. There are characteristic peaks at 8.62, 9.49, 12.32, 13.39, 15.52, 19.15, 19.17, 21.42 and 22.78, wherein the error range of each characteristic peak 2 ⁇ is ⁇ 0.2.
- the invention also provides a method of preparing a C crystal form, characterized in that the method comprises:
- the compound represented by the formula (I) is dissolved in a good solvent, an anti-solvent is added, crystallized, filtered, and dried to obtain a target C crystal form;
- the good solvent is selected from an ether solvent, and the ether solvent is selected from 1 , 4-dioxane
- the anti-solvent is selected from the group consisting of aliphatic hydrocarbons or alicyclic hydrocarbon solvents, the aliphatic hydrocarbon solvent is selected from n-heptane, and the alicyclic hydrocarbon solvent is selected from cyclohexane
- the method for crystallizing is selected from the group consisting of room temperature crystallization, cooling crystallization, crystallization of a volatile solvent or addition of a seed crystal to induce crystallization.
- the present invention also provides a crystal form of D of the compound of the formula (I), characterized in that an X-ray powder diffraction pattern represented by a diffraction angle 2 ⁇ angle is obtained using Cu-K ⁇ radiation, and the diffraction angle 2 ⁇ angle is 8.41. There are characteristic peaks at 8.85, 11.38, 12.18, 13.45, 15.15, 16.73, 17.59, 17.68, 20.45, 21.51, 22.72, 24.53, 24.91 and 27.11, wherein the error range of each characteristic peak 2 ⁇ is ⁇ 0.2.
- the diffraction angle 2 ⁇ angles are 8.41, 8.85, 10.15, 11.38, 12.18, 13.45, 14.40, 15.15, 16.73, 17.59, 17.68, 18.42, 18.91, 19.22, 20.45, 21.15, 21.51, 22.11, 22.72, 24.03, 24.53, 24.91, 25.54, 26.54, 27.11, 27.61, 29.04, 30.49, 31.31, 33.00, 33.88, 35.52, 37.53, 40.46, 41.36, 42.40 and 44.02 have characteristic peaks, wherein the error range of each characteristic peak 2 ⁇ is ⁇ 0.2.
- the invention also provides a method of preparing a crystalline form of D, characterized in that the method is selected from the group consisting of:
- a mixed solvent of an ether and water a mixed solvent of an alcohol and an aliphatic hydrocarbon, or a mixed solvent of an ether and an aliphatic hydrocarbon
- the alcohol solvent being selected from the group consisting of methanol, ethanol or isopropanol
- the ether solvent is selected From tetrahydrofuran or 1,4-dioxane
- the aliphatic hydrocarbon solvent is selected from n-heptane
- the crystallization method is selected from room temperature crystallization, cooling crystallization, volatile solvent crystallization or seed crystal precipitation analysis crystal;
- the compound represented by the formula (I) is dissolved in a good solvent, an anti-solvent is added, crystallized, filtered, and dried to obtain a target D crystal form;
- the good solvent is selected from an alcohol or an ether solvent,
- the alcohol solvent is selected from the group consisting of methanol or isopropanol
- the ether solvent is selected from tetrahydrofuran
- the anti-solvent is selected from water
- the good solvent is selected from the group consisting of ether solvents
- the ether solvent is selected from tetrahydrofuran.
- the compound represented by the formula (I) is added to a solvent, beaten, filtered, and dried to obtain a target crystal form D;
- the solvent is selected from the group consisting of water, esters, ethers, aliphatic hydrocarbons, and alicyclic hydrocarbons.
- a nitroalkane solvent an aromatic hydrocarbon, an alcohol, a nitrile, a halogenated hydrocarbon, a ketone, a sulfoxide, an amide, a mixed solvent of an alcohol and an ether, a mixed solvent of an alcohol and water, or a kind Or a mixed solvent of a plurality of alcohols;
- the ester solvent is selected from the group consisting of ethyl acetate, isopropyl acetate or butyl acetate
- the ether solvent is selected from the group consisting of tetrahydrofuran, 1,4-dioxane, and propylene glycol
- the aliphatic hydrocarbon is selected from n-heptane
- the alicyclic hydrocarbon is selected from cyclohexane
- the nitroalkane solvent is selected from the group consisting of nitromethane
- the aromatic hydrocarbon The solvent is selected from the group consisting
- the ketone solvent is selected from the group consisting of acetone
- the sulfoxides are selected from the group consisting of dimethyl sulfoxide
- the mixed solvent of the one or more alcohols is selected from the group consisting of methanol and B.
- the invention also provides a method for preparing a D crystal single crystal, characterized in that the method comprises:
- the compound represented by the formula (I) is dissolved in a solvent, crystallized, filtered, and dried to obtain a single crystal of the target D crystal form;
- the solvent is selected from a mixed solvent of an alcohol and water, and the alcohol solvent is selected from the group consisting of Methanol or ethanol; the ratio of the alcohol to water is 20:1-1:20, preferably 6:1;
- the method of crystallization is selected from room temperature crystallization, cooling crystallization, volatile solvent crystallization or seeding Induced crystallization.
- the invention further relates to a pharmaceutical composition of Form A, Form B, Form C, Form D of Form D, further comprising one or more pharmaceutically acceptable carriers, diluents or excipients.
- the present invention also relates to the use of Form A, Form B, Form C, Form D of D, and pharmaceutical compositions for the preparation of a medicament for the treatment of a disease associated with an EZH2 inhibitor.
- the EZH2 inhibitor-related disease is selected from the group consisting of lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdoid tumor, synovial sarcoma, mesothelioma, Cervical, colon, rectal, gastric, pancreatic, brain, skin, oral, bone, kidney, bladder, fallopian tube, ovarian, peritoneal, glioma, glial Tumor, head and neck tumor and myeloma; preferably lymphoma, leukemia, breast cancer, lung cancer, prostate cancer, ovarian cancer, liver cancer, melanoma, rhabdoid tumor, synovial sarcoma and mesothelioma; It is chronic myeloid leukemia, acute myeloid leukemia and mixed cell line leukemia; the lymphoma is preferably non-Hodgkin's lymphoma,
- the crystal form of the obtained compound of the formula (I) was subjected to structure measurement and crystal form study by X-ray powder diffraction pattern (XRPD) and differential scanning calorimetry (DSC).
- XRPD X-ray powder diffraction pattern
- DSC differential scanning calorimetry
- the method of crystal recrystallization is not particularly limited and can be carried out by a usual recrystallization operation method.
- the compound of the formula (I) can be dissolved in an organic solvent and then added to an anti-solvent to crystallize. After the crystallization is completed, it can be dried by filtration to obtain a desired crystal.
- the method for crystallization of the present invention includes room temperature crystallization, cooling crystallization, crystallization of a volatile solvent, seed crystal induced crystallization, and the like, and the cooling temperature is selected from 40 ° C or lower, preferably from -10 ° C to 40 ° C.
- the starting material used in the method for preparing a crystal form of the present invention may be any compound of the formula (I), and the specific forms include, but are not limited to, amorphous, arbitrary crystal forms and the like.
- C 1-6 alkyl group of the present invention means a linear or branched alkyl group having 1 to 6 carbon atoms, and specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl.
- n-butyl isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 3 -methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, 1,2-dimethylpropyl, and the like.
- ether solvent means a chain compound or a cyclic compound having an ether bond -O- and having 1 to 10 carbon atoms, and specific examples include, but are not limited to, tetrahydrofuran, diethyl ether, and propylene glycol methyl ether. , methyl tert-butyl ether or 1,4-dioxane.
- the "alcohol solvent” as used in the present invention means a group derived from one or more "hydroxyl groups” substituted with one or more hydrogen atoms on the "C 1-6 alkyl group", said "hydroxyl group” and "C” 1-6 alkyl” is as defined above, and specific examples include, but are not limited to, methanol, ethanol, isopropanol, n-propanol, isoamyl alcohol or trifluoroethanol.
- ester solvent means a combination of a lower organic acid having 1 to 4 carbon atoms and a lower alcohol having 1 to 6 carbon atoms, and specific examples include, but are not limited to, acetic acid. Ethyl ester, isopropyl acetate or butyl acetate.
- the "ketone solvent” as used in the present invention means a compound in which a carbonyl group (-C(O)-) is bonded to two hydrocarbon groups, and the ketone can be classified into an aliphatic ketone, an alicyclic ketone, an aromatic ketone according to a hydrocarbon group in the molecule.
- Saturated ketones and unsaturated ketones specific examples include, but are not limited to, acetone, acetophenone, methyl isobutyl ketone or methyl pyrrolidone.
- nitrile solvent as used in the present invention means a group derived from one or more hydrogen atoms on one or more "cyano" substituted “C 1-6 alkyl", said “cyano” and “C 1-6 alkyl” is as defined above, and specific examples include, but are not limited to, acetonitrile or propionitrile.
- aliphatic hydrocarbon solvent refers to a carbon having a basic property of an aliphatic compound and having carbon atoms in the molecule which are connected to each other in a chain, and the carbon atoms are 1-10.
- Hydrogen compounds such as saturated aliphatic hydrocarbons include alkane solvents, specific examples including, but not limited to, n-butane, n-pentane, n-hexane or n-heptane.
- alicyclic hydrocarbon solvent refers to a hydrocarbon compound having a cyclic carbon skeleton and having similar properties to aliphatic hydrocarbons and having a number of ring atoms of 1-8, and specific examples include, but are not limited to, rings. Pentane or cyclohexane.
- amide solvent as used in the present invention means a compound containing a carbonylamino group (-C(O)N-) and having 1 to 10 carbon atoms, and specific examples include, but are not limited to, N, N-dimethyl Carboxamide or N,N-dimethylacetamide.
- aromatic hydrocarbon solvent refers to a conjugated system having a closed ring in a molecule, and a general term for a carbon ring compound and a derivative thereof having a ⁇ electron number in accordance with the Huckel rule, and specific examples include but are not limited to: Propyl benzene or xylene.
- halogenated hydrocarbon solvent as used in the present invention means a group derived by substituting one or more "halogen atoms” for one or more hydrogen atoms on a "C 1-6 alkyl group", said "halogen atom” And “C 1-6 alkyl” are as defined above, and specific examples include, but are not limited to, methyl chloride, dichloromethane, chloroform or carbon tetrachloride.
- nitroalkane solvent as used in the present invention means a group derived by one or more "nitro” substituted one or more hydrogen atoms on a "C 1-6 alkyl group", said “C 1 -6 alkyl” is as defined above, and specific examples include, but are not limited to, nitromethane.
- the “mixed solvent” as used in the present invention means a solvent obtained by mixing one or more different kinds of organic solvents in a certain ratio, or a solvent obtained by mixing an organic solvent and water in a certain ratio;
- the mixed solvent is preferably a mixed solvent of one or more alcohols, a mixed solvent of an alcohol and an ether, a mixed solvent of an alcohol and an aliphatic hydrocarbon or an ether, a mixed solvent of an aliphatic hydrocarbon, a mixed solvent of an alcohol and water, and a halogenated a mixed solvent of a hydrocarbon and a nitrile solvent, a mixed solvent of an amide solvent and water, a mixed solvent of an ether and water; an alcohol, an ether, an aliphatic hydrocarbon, a halogenated hydrocarbon, an amide, or a nitrile As defined above.
- the "differential scanning calorimetry or DSC” as used in the present invention refers to measuring the temperature difference and heat flow difference between a sample and a reference during temperature rise or constant temperature of the sample to characterize all physical changes and chemistry related to thermal effects. Change to get the phase change information of the sample.
- the "2 ⁇ or 2 ⁇ angle" as used in the present invention means a diffraction angle, ⁇ is a Bragg angle, and the unit is ° or degree, and the error range of 2 ⁇ is ⁇ 0.1 to ⁇ 0.5, preferably ⁇ 0.1 to ⁇ 0.3, more preferably ⁇ 0.2.
- the "plane spacing or interplanar spacing (d value)" means that the spatial lattice selects three unit vectors a, b, c which are not parallel to each other and adjacent two lattice points, and they point the points.
- the parallelepiped unit which is divided into juxtapositions, is called the interplanar spacing.
- the spatial lattice is divided according to the determined parallelepiped unit lines, and a set of linear grids is obtained, which is called a space lattice or a lattice.
- the lattice and the lattice reflect the periodicity of the crystal structure by geometric points and lines, respectively, and the interplanar spacing (ie, the distance between two adjacent parallel crystal planes) is different; Or ang.
- the pharmaceutical compositions of the present invention may also be administered to a patient or subject in need of such treatment by any suitable mode of administration, such as oral, parenteral, rectal, pulmonary or topical administration.
- the pharmaceutical composition can be formulated into an oral preparation, such as an oral solid preparation such as a tablet, a capsule, a pill, a granule, or the like; or an oral liquid preparation such as an oral solution or an oral mixture. Suspension, syrup, and the like.
- the pharmaceutical preparation may further contain a suitable filler, binder, disintegrant, lubricant, and the like.
- the pharmaceutical preparation When used for parenteral administration, the pharmaceutical preparation can be prepared as an injection, including an injection, a sterile powder for injection, and a concentrated solution for injection.
- the pharmaceutical composition When formulated as an injection, the pharmaceutical composition can be produced by a conventional method in the existing pharmaceutical field.
- an additional agent may be added to the pharmaceutical preparation, and a suitable additional agent may be added depending on the nature of the drug.
- the pharmaceutical preparation When used for rectal administration, can be formulated into a suppository or the like.
- the pharmaceutical preparation For pulmonary administration, the pharmaceutical preparation can be formulated as an inhalant or a spray.
- the Form A, Form B, Form C, Form D of the compound of Formula (I) of the present invention is present in a pharmaceutical composition or drug in a therapeutically and/or prophylactically effective amount. in. In certain preferred embodiments, Form A, Form B, Form C, Form D of the compound of Formula (I) of the present invention are present in a pharmaceutical composition or medicament in unit dosage form.
- the compound of the formula (I) of the present invention can be used for the preparation of a medicament for treating diseases associated with EZH2 inhibitors. Accordingly, the present application also relates to the use of Form A, Form B, Form C, Form D of the compound of formula (I) of the present invention for the preparation of a medicament for the treatment of a drug associated with an EZH2 inhibitor. Use in medicines for diseases. Furthermore, the present application relates to a method of inhibiting a disease associated with an EZH2 inhibitor, which comprises administering to a subject in need thereof a therapeutically and/or prophylactically effective amount of a crystal of a compound of the formula (I) according to the invention. Form, Form B, Form C, Form D, or a pharmaceutical composition of the invention.
- the disease is a disease associated with an EZH2 inhibitor selected from the group consisting of pain.
- the compound of the formula (I) prepared by the present invention has good stability, high purity, and high crystal purity, and obtains the crystal form of the A crystal form and the D crystal form.
- the single crystal, the A crystal form, the B crystal form, the C crystal form and the D crystal form of the compound of the formula (I) obtained by the technical scheme of the present invention can meet the medicinal requirements for production, transportation and storage, and the production process is stable and reproducible and controllable. Can adapt to industrial production.
- Figure 1 is an XRPD pattern of the crystalline form of Compound A of formula (I).
- Figure 2 is an XRPD pattern of the crystalline form of Compound B of formula (I).
- Figure 3 is a DSC chart of the crystalline form of Compound B of formula (I).
- Figure 4 is an XRPD pattern of the crystalline form of Compound C of formula (I).
- Figure 5 is a DSC chart of the crystalline form of Compound C of formula (I).
- Figure 6 is an XRPD pattern of the crystalline form of Compound D of formula (I).
- Figure 7 is a DSC chart of the crystalline form of Compound D of formula (I).
- Figure 8 is a first cycle diagram of DVS of the compound D crystal form of the formula (I).
- Figure 9 is a second cycle diagram of DVS of the compound D crystal form of the formula (I).
- Figure 10 is an XRPD pattern of the compound B of the formula (I) for 0 days.
- Figure 11 is an XRPD pattern of the crystalline form of Compound B of Formula (I) after 20 days at 25 ° C and RH 65%.
- Figure 12 is an XRPD pattern of the compound D of the formula (I) for 0 days.
- Figure 13 is an XRPD pattern of the compound D crystal form of the formula (I) after 40 days at 40 ° C and RH 75%.
- Figure 14 is an XRPD pattern of the compound D crystal form of the formula (I) after 20 days at 25 ° C and RH 65%.
- Figure 15 is a perspective view showing the X-ray single crystal diffraction molecule of the compound A of the formula (I).
- Figure 16 is a perspective view showing the X-ray single crystal diffraction molecule of the compound D of the formula (I).
- Methyl 6-bromo-5-ethylbenzofuran-4-carboxylate 1 g (11.0 g, 39 mmol), tetrahydro-2H-pyran-4-amine (5.89 g, 58 mmol), tris(dibenzylidene) Acetone) dipalladium (3.6 g, 3.9 mmol), (.9 mmol) bis-(diphenylphosphino)-1,1'-binaphthyl (4.86 g, 7.8 mmol), cesium carbonate (38 g, 117 mmol) The reaction was stirred at 100 ° C for 12 hours in 100 mL of toluene.
- the DSC spectrum is shown in Fig. 3.
- an endothermic peak and an exothermic peak appear, and the exothermic peak starts at 123.69 °C, and the initial melting temperature is about At 206.31 ° C, this crystal form is defined as B crystal form, and its characteristic peak positions are shown in the following table:
- Figure 10 of the accompanying drawings is an XRPD pattern of B crystal form 0 day
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (15)
- 如权利要求1所述的A晶型,其特征在于,所述衍射角2θ角在7.60、8.51、10.37、11.16、11.80、12.38、12.89、13.52、13.73、14.03、14.48、15.23、15.99、16.10、16.43、16.82、16.99、17.35、18.24、18.92、19.17、20.68、20.82、21.57、21.91、22.57、22.76、22.88、23.53、23.68、24.00、24.29、24.47、24.91、25.24、25.72、25.90、27.23、27.74和35.63处有特征峰,其中,每个特征峰2θ的误差范围为±0.2。
- 一种制备权利要求1-2任一项所述的A晶型方法,其特征在于,所述方法选自方法一,将式(I)所示化合物溶解于溶剂中,析晶,过滤,干燥后即得目标A晶型;所述溶剂选自酰胺类溶剂、酰胺类溶剂与水的混合溶剂、卤代烃类与腈类的混合溶剂,所述酰胺类溶剂选自N,N-二甲基甲酰胺或N,N-二甲基乙酰胺,所述卤代烃类溶剂选自二氯甲烷,所选腈类溶剂选自乙腈;所述析晶的方法选自室温析晶、冷却析晶、挥发溶剂析晶或加入晶种诱导析晶;方法二,将式(I)所示化合物溶解于良溶剂中,加入反溶剂,析晶,过滤,干燥后即得目标A晶型;所述良溶剂选自醇类溶剂,所述醇类溶剂选自甲醇或异丙醇,所述反溶剂选自水;所述析晶的方法选自室温析晶、冷却析晶、挥发溶剂析晶或加入晶种诱导析晶;方法三,将式(I)所示化合物加入溶剂中,打浆,过滤,干燥后即得目标A晶型;所述溶剂选自酰胺类溶剂与水的混合溶剂、卤代烃类与腈类溶剂的混合溶剂, 所述酰胺类溶剂选自N,N-二甲基甲酰胺或N,N-二甲基乙酰胺,所述卤代烃类溶剂选自二氯甲烷,所选腈类溶剂选自乙腈。
- 如权利要求1所述式(I)所示化合物的B晶型,其特征在于:使用Cu-Kα辐射,得到以衍射角2θ角度表示的X-射线粉末衍射图谱,其衍射角2θ角在6.31、7.24、10.99、12.07、14.56、17.94、19.13、19.71、21.48、24.15、27.10和28.83处有特征峰,其中,每个特征峰2θ的误差范围为±0.2。
- 如权利要求4所述的B晶型,其特征在于,所述衍射角2θ角在6.31、7.24、8.92、10.38、10.99、12.07、14.56、15.10、16.36、17.29、17.94、19.13、19.71、21.12、21.48、22.59、24.15、25.45、26.28、26.52、27.10、28.83、30.07、31.37、32.56、33.65、34.64、36.09、37.13和40.04处有特征峰,其中,每个特征峰2θ的误差范围为±0.2。
- 一种制备如权利要求4-5中任一项所述B晶型的方法,其特征在于,所述方法选自:方法一,将式(I)所示化合物溶解于溶剂中,析晶,过滤,干燥后即得目标B晶型;所述溶剂选自乙醇;所述析晶的方法选自室温析晶、冷却析晶、挥发溶剂析晶或加入晶种诱导析晶;方法二,将式(I)所示化合物溶解于良溶剂中,加入反溶剂,析晶,过滤,干燥后即得目标B晶型;所述良溶剂选自乙醇,所述反溶剂选自水;所述析晶的方法选自室温析晶、冷却析晶、挥发溶剂析晶或加入晶种诱导析晶。
- 如权利要求1所述式(I)所示化合物的C晶型,其特征在于:使用Cu-Kα辐射,得到以衍射角2θ角度表示的X-射线粉末衍射图谱,其衍射角2θ角在7.40、8.62、9.49、12.32、13.39、15.52、19.15、19.17、21.42和22.78处有特征峰,其中,每个特征峰2θ的误差范围为±0.2。
- 如权利要求7所述的C晶型,其特征在于,所述衍射角2θ角在7.40、8.62、9.49、9.96、11.12、12.32、13.39、14.21、14.85、15.52、16.50、17.67、18.28、19.15、19.17、20.06、20.80、21.42、21.89、22.20、22.78、23.41、24.74、25.34、26.70、27.38、28.64、29.63、30.20和31.15处有特征峰,其中,每个特征峰2θ的误差范围为±0.2。
- 一种制备如权利要求7-8中任一项所述C晶型的方法,其特征在于,所述方法包括:将式(I)所示化合物溶解于良溶剂中,加入反溶剂,析晶,过滤,干燥后即得 目标C晶型;所述良溶剂选自醚类溶剂,所述醚类溶剂选自1,4-二氧六环,所述反溶剂选自脂肪烃类或脂环烃类溶剂,所述脂肪烃类溶剂选自正庚烷,所述脂环烃类溶剂选自环己烷;所述析晶的方法选自室温析晶、冷却析晶、挥发溶剂析晶或加入晶种诱导析晶。
- 如权利要求1所述式(I)所示化合物的D晶型,其特征在于:使用Cu-Kα辐射,得到以衍射角2θ角度表示的X-射线粉末衍射图谱,其衍射角2θ角在8.41、8.85、11.38、12.18、13.45、15.15、16.73、17.59、17.68、20.45、21.51、22.72、24.53、24.91和27.11处有特征峰,其中,每个特征峰2θ的误差范围为±0.2。
- 如权利要求10所述的D晶型,其特征在于,所述衍射角2θ角在8.41、8.85、10.15、11.38、12.18、13.45、14.40、15.15、16.73、17.59、17.68、18.42、18.91、19.22、20.45、21.15、21.51、22.11、22.72、24.03、24.53、24.91、25.54、26.54、27.11、27.61、29.04、30.49、31.31、33.00、33.88、35.52、37.53、40.46、41.36、42.40和44.02处有特征峰,其中,每个特征峰2θ的误差范围为±0.2。
- 一种制备如权利要求10-11中任一项所述D晶型的方法,其特征在于,所述方法选自:方法一,将式(I)所示化合物溶解于溶剂中,析晶,过滤,干燥后即得目标D晶型;所述溶剂选自醇类溶剂、醚类溶剂、醇类与水的混合溶剂、醚类与水的混合溶剂、醇类与脂肪烃类的混合溶剂或醚类与脂肪烃类的混合溶剂,所述醇类溶剂选自甲醇、乙醇或异丙醇,所述醚类溶剂选自四氢呋喃或1,4-二氧六环,所述脂肪烃类溶剂选自正庚烷;所述析晶的方法选自室温析晶、冷却析晶、挥发溶剂析晶或加入晶种诱导析晶;方法二,将式(I)所示化合物溶解于良溶剂中,加入反溶剂,析晶,过滤,干燥后即得目标D晶型;所述良溶剂选自醇类或醚类溶剂,所述醇类溶剂选自甲醇或异丙醇,所述醚类溶剂选自四氢呋喃,所述反溶剂选自水;或者所述良溶剂选自醚类溶剂,所述醚类溶剂选自四氢呋喃,所述反溶剂选自脂肪烃类或脂环烃类溶剂,所述脂肪烃类溶剂选自正庚烷,所述脂环烃类溶剂选自环己烷;所述析晶的方法选自室温析晶、冷却析晶、挥发溶剂析晶或加入晶种诱导析晶;方法三,将式(I)所示化合物加入溶剂中,打浆,过滤,干燥后即得目标晶型D;所述溶剂选自水、酯类、醚类、脂肪烃类、脂环烃类、硝基烷烃类溶剂、芳香烃类、醇类、腈类、卤代烃类、酮类、亚砜类、酰胺类、醇类与醚类的混合溶剂、醇类与水的混合溶剂或一种或多种醇类的混合溶剂;其中所述酯类溶剂选自乙酸乙酯、乙酸异丙酯或乙酸丁酯,所述醚类溶剂选自四氢呋喃、1,4-二氧六环、丙二醇甲醚或甲基叔丁基醚,所述脂肪烃类选自正庚烷,所述脂环烃类选自环己烷, 所述硝基烷烃类溶剂选自硝基甲烷,所述芳香烃类溶剂选自二甲苯或异丙基苯,所述醇类溶剂选自甲醇、乙醇或异丙醇,所述腈类溶剂选自乙腈,所述卤代烃类溶剂选自二氯甲烷,所述酮类溶剂选自丙酮,所述亚砜类选自二甲基亚砜,所述酰胺类溶剂选自N,N-二甲基甲酰胺或N,N-二甲基乙酰胺,所述一种或多种醇类的混合溶剂选自甲醇与乙醇的混合溶剂、甲醇与异丙醇的混合溶剂或乙醇与异丙醇的混合溶剂。
- 含有权利要求1-2中任一项所述的A晶型、权利要求4-5中任一项所述的B晶型、权利要求7-8中任一项所述的C晶型、权利要求10-11中任一项所述的D晶型的药物组合物,其特征在于还包含一种或多种药学上可接受的载体、稀释剂或赋形剂。
- 含有权利要求1-2中任一项所述的A晶型、权利要求4-5中任一项所述的B晶型、权利要求7-8中任一项所述的C晶型、权利要求10-11中任一项所述的D晶型、权利要求13所述药物组合物在制备治疗与EZH2抑制剂相关疾病的药物中的用途。
- 根据权利要求14所述的用途,其中所述EZH2抑制剂相关疾病选自淋巴瘤、白血病、乳腺癌、肺癌、前列腺癌、卵巢癌、肝癌、黑色素瘤、横纹肌样瘤、滑膜肉瘤、间皮瘤、宫颈癌、结肠癌、直肠癌、胃癌、胰腺癌、脑癌、皮肤癌、口腔癌、骨癌、肾癌、膀胱癌、输卵管肿瘤、卵巢瘤、腹膜肿瘤、神经胶质瘤、神经胶母细胞瘤、头颈部肿瘤和骨髓瘤;优选为淋巴瘤、白血病、乳腺癌、肺癌、前列腺癌、卵巢癌、肝癌、黑色素瘤、横纹肌样瘤、滑膜肉瘤和间皮瘤;所述的白血病优选为慢性骨髓白血病、急性骨髓白血病和混合细胞系白血病;所述的淋巴瘤优选为非霍奇金淋巴瘤、弥漫大B细胞淋巴瘤或滤泡性淋巴瘤。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112019021023A BR112019021023A2 (pt) | 2017-05-18 | 2018-05-17 | cristal de base livre de derivado de benzofurano e método de preparação. |
MX2019012967A MX2019012967A (es) | 2017-05-18 | 2018-05-17 | Cristal de base libre de derivados benzofurano y metodo de preparacion. |
US16/612,168 US11155537B2 (en) | 2017-05-18 | 2018-05-17 | Crystal of benzofuran derivative free base and preparation method |
KR1020197035449A KR102612379B1 (ko) | 2017-05-18 | 2018-05-17 | 벤조푸란 유도체 자유 염기의 결정 및 제조 방법 |
CA3058496A CA3058496A1 (en) | 2017-05-18 | 2018-05-17 | Crystal of benzofuran derivative free base and preparation method |
MYPI2019006338A MY198008A (en) | 2017-05-18 | 2018-05-17 | Crystal of benzofuran derivative free base and preparation method |
EP18802467.3A EP3626715A4 (en) | 2017-05-18 | 2018-05-17 | CRYSTAL OF A BENZOFURAND DERIVATIVE-FREE BASE AND MANUFACTURING PROCESS |
RU2019136363A RU2791189C2 (ru) | 2017-05-18 | 2018-05-17 | Кристаллические формы свободного основания производного бензофурана и способ получения |
AU2018269268A AU2018269268B2 (en) | 2017-05-18 | 2018-05-17 | Crystal of benzofuran derivative free base and preparation method |
CN201880004345.0A CN109937200B (zh) | 2017-05-18 | 2018-05-17 | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 |
JP2019557445A JP7257328B2 (ja) | 2017-05-18 | 2018-05-17 | ベンゾフラン誘導体遊離塩基の結晶およびその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710350574.5 | 2017-05-18 | ||
CN201710350574 | 2017-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018210302A1 true WO2018210302A1 (zh) | 2018-11-22 |
Family
ID=64273357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/087272 WO2018210302A1 (zh) | 2017-05-18 | 2018-05-17 | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11155537B2 (zh) |
EP (1) | EP3626715A4 (zh) |
JP (1) | JP7257328B2 (zh) |
KR (1) | KR102612379B1 (zh) |
CN (1) | CN109937200B (zh) |
AU (1) | AU2018269268B2 (zh) |
BR (1) | BR112019021023A2 (zh) |
CA (1) | CA3058496A1 (zh) |
MX (1) | MX2019012967A (zh) |
MY (1) | MY198008A (zh) |
TW (1) | TWI772424B (zh) |
WO (1) | WO2018210302A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020228591A1 (zh) * | 2019-05-10 | 2020-11-19 | 江苏恒瑞医药股份有限公司 | 一种6-取代氨基苯并呋喃化合物的制备方法 |
WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
WO2012050532A1 (en) | 2010-10-15 | 2012-04-19 | Agency For Science, Technology And Research | Combination treatment of cancer |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
WO2012142504A1 (en) | 2011-04-13 | 2012-10-18 | Epizyme, Inc. | Aryl-or heteroaryl-substituted benzene compounds |
WO2012142513A1 (en) | 2011-04-13 | 2012-10-18 | Epizyme, Inc. | Substituted benzene compounds |
WO2013039988A1 (en) | 2011-09-13 | 2013-03-21 | Glax0Smithkline Llc | Azaindazoles |
WO2013049770A2 (en) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
WO2014097041A1 (en) | 2012-12-21 | 2014-06-26 | Pfizer Inc. | Aryl and heteroaryl fused lactams |
WO2015141616A1 (ja) | 2014-03-17 | 2015-09-24 | 第一三共株式会社 | 1,3-ベンゾジオキソール誘導体 |
WO2017084494A1 (zh) | 2015-11-19 | 2017-05-26 | 江苏恒瑞医药股份有限公司 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
-
2018
- 2018-05-17 CN CN201880004345.0A patent/CN109937200B/zh active Active
- 2018-05-17 KR KR1020197035449A patent/KR102612379B1/ko active IP Right Grant
- 2018-05-17 BR BR112019021023A patent/BR112019021023A2/pt active Search and Examination
- 2018-05-17 JP JP2019557445A patent/JP7257328B2/ja active Active
- 2018-05-17 MX MX2019012967A patent/MX2019012967A/es unknown
- 2018-05-17 CA CA3058496A patent/CA3058496A1/en active Pending
- 2018-05-17 US US16/612,168 patent/US11155537B2/en active Active
- 2018-05-17 MY MYPI2019006338A patent/MY198008A/en unknown
- 2018-05-17 WO PCT/CN2018/087272 patent/WO2018210302A1/zh active Application Filing
- 2018-05-17 EP EP18802467.3A patent/EP3626715A4/en not_active Withdrawn
- 2018-05-17 AU AU2018269268A patent/AU2018269268B2/en active Active
- 2018-05-17 TW TW107116783A patent/TWI772424B/zh active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
WO2012050532A1 (en) | 2010-10-15 | 2012-04-19 | Agency For Science, Technology And Research | Combination treatment of cancer |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
WO2012142504A1 (en) | 2011-04-13 | 2012-10-18 | Epizyme, Inc. | Aryl-or heteroaryl-substituted benzene compounds |
WO2012142513A1 (en) | 2011-04-13 | 2012-10-18 | Epizyme, Inc. | Substituted benzene compounds |
WO2013039988A1 (en) | 2011-09-13 | 2013-03-21 | Glax0Smithkline Llc | Azaindazoles |
WO2013049770A2 (en) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
CN103987842A (zh) * | 2011-09-30 | 2014-08-13 | 葛兰素史密斯克莱有限责任公司 | 治疗癌症的方法 |
WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
WO2014097041A1 (en) | 2012-12-21 | 2014-06-26 | Pfizer Inc. | Aryl and heteroaryl fused lactams |
WO2015141616A1 (ja) | 2014-03-17 | 2015-09-24 | 第一三共株式会社 | 1,3-ベンゾジオキソール誘導体 |
WO2017084494A1 (zh) | 2015-11-19 | 2017-05-26 | 江苏恒瑞医药股份有限公司 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 113, no. 13, 1991, pages 4931 - 6 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020228591A1 (zh) * | 2019-05-10 | 2020-11-19 | 江苏恒瑞医药股份有限公司 | 一种6-取代氨基苯并呋喃化合物的制备方法 |
CN113767096A (zh) * | 2019-05-10 | 2021-12-07 | 江苏恒瑞医药股份有限公司 | 一种6-取代氨基苯并呋喃化合物的制备方法 |
CN113767096B (zh) * | 2019-05-10 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 一种6-取代氨基苯并呋喃化合物的制备方法 |
WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
Also Published As
Publication number | Publication date |
---|---|
MY198008A (en) | 2023-07-25 |
KR20200006551A (ko) | 2020-01-20 |
CN109937200A (zh) | 2019-06-25 |
TW201900639A (zh) | 2019-01-01 |
CA3058496A1 (en) | 2018-11-22 |
JP7257328B2 (ja) | 2023-04-13 |
CN109937200B (zh) | 2020-09-11 |
KR102612379B1 (ko) | 2023-12-12 |
EP3626715A1 (en) | 2020-03-25 |
US20210130333A1 (en) | 2021-05-06 |
AU2018269268A1 (en) | 2019-11-07 |
JP2020519569A (ja) | 2020-07-02 |
US11155537B2 (en) | 2021-10-26 |
TWI772424B (zh) | 2022-08-01 |
RU2019136363A3 (zh) | 2021-12-29 |
MX2019012967A (es) | 2020-01-20 |
AU2018269268B2 (en) | 2022-01-06 |
RU2019136363A (ru) | 2021-06-18 |
BR112019021023A2 (pt) | 2020-05-05 |
EP3626715A4 (en) | 2021-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI682929B (zh) | 一種阿片樣物質受體(mor)激動劑的鹽、其富馬酸鹽i晶型及製備方法 | |
EP3248983B1 (en) | Crystal form a of obeticholic acid and preparation method therefor | |
WO2018210302A1 (zh) | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 | |
JP2023157909A (ja) | 2-(5-(4-(2-モルホリノエトキシ)フェニル)ピリジン-2-イル)-n-ベンジルアセトアミドの固体形態 | |
WO2018072742A1 (zh) | 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法 | |
WO2018133823A1 (zh) | 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法 | |
WO2017041622A1 (zh) | 一种雄性激素受体抑制剂的结晶形式及其制备方法 | |
TWI745764B (zh) | 一種鴉片類物質受體激動劑的結晶形式及製備方法 | |
TWI666207B (zh) | 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法 | |
RU2791189C2 (ru) | Кристаллические формы свободного основания производного бензофурана и способ получения | |
TWI717859B (zh) | 一種鴉片類物質受體激動劑的結晶形式及製備方法 | |
RU2779119C2 (ru) | Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения | |
WO2023222103A1 (zh) | 一种三嗪二酮类衍生物的晶型及制备方法 | |
WO2019001551A1 (zh) | 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法 | |
WO2017047791A1 (ja) | ピペラジン化合物の新規結晶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18802467 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3058496 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019021023 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019557445 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018269268 Country of ref document: AU Date of ref document: 20180517 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197035449 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019136363 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2018802467 Country of ref document: EP Effective date: 20191218 |
|
ENP | Entry into the national phase |
Ref document number: 112019021023 Country of ref document: BR Kind code of ref document: A2 Effective date: 20191007 |